Indiana GLP-1 Med Spa Compliance Rules 2026

Indiana spent years as one of the quietest states in aesthetics regulation and became, in a single legislative session, the loudest. Senate Bill 282 was signed by Governor Mike Braun on March 5, 2026, and it did something no other state had done in quite this shape: it wrote a medical spa chapter and a GLP-1 compounding chapter into the same act, on the theory that the aesthetics clinic and the compounded weight-loss supply chain are the same story told from two ends. If you run a semaglutide or tirzepatide programme in Indiana, that pairing is not a legislative curiosity. It is the reason your practice now has three regulators reading the same patient file.

This guide is Indiana-only. It does not re-explain how GLP-1 receptor agonists work, what a titration ladder looks like, or how a med spa builds a weight-loss programme from nothing — our national GLP-1 med spa compliance guide is where the general mechanics live, and every reader who wants the model rather than the jurisdiction should start there. What follows is the part that changes at the Indiana state line, and it opens with the question nobody has answered in print.

Does SB 282 Actually Reach a GLP-1 Weight-Loss Programme?

This is the question Indiana owners are asking and the one the trade coverage has mostly skipped, because the coverage was written for injectors. The answer is more interesting than a yes or a no: it is a clear yes for the ordinary case and a genuinely open question at one specific edge, and knowing which side of that edge you sit on is worth more than a confident answer would be.

The three elements of the definition

The new chapter defines a medical spa as a facility or practice that offers or provides medical health care services, engages in the preparation, administration, or dispensing of prescription drugs, and holds itself out as being focused on cosmetic or lifestyle treatments. The examples the drafters attached to that third element are the tell: botulinum toxin, dermal fillers, cosmetic laser use — and weight loss. Weight loss is not something a regulator has to squeeze into a general category. It is written into the definition alongside Botox.

Run the elements against an ordinary Indiana weight-loss suite. It provides medical health care services, because evaluating a patient for semaglutide and treating them with it is medical care. It prepares, administers, or dispenses a prescription drug, because that is what a GLP-1 programme is. And it holds itself out as focused on a lifestyle treatment, because that is what the website says. Three for three, on the face of the statute, without an argument.

Where the answer stops being clear

The exclusions are where honest analysis has to slow down. The term does not reach facilities otherwise licensed by the state, and the location provision written into the act treats a medical spa, a physician's office, and other health care facilities as distinct places. Read together, those two features leave room for a reading in which a physician-office-based practice is not a medical spa for chapter purposes even when it prescribes the same drug to the same patient.

Add the third element back and the ambiguity sharpens. Holds itself out as being focused on cosmetic or lifestyle treatments is a marketing test, not a clinical one. A bariatric or obesity medicine practice that presents GLP-1 therapy as the treatment of a diagnosed metabolic disease — with a diagnosis code, comorbidity screening, and no aesthetic language anywhere in its marketing — has a real argument that it does not hold itself out as focused on lifestyle treatments at all. A med spa that runs the identical clinical protocol under the words slim, reset, or longevity has no such argument.

The honest verdict, and what to do with it

So: for the overwhelming majority of Indiana practices reading this, SB 282 applies and the question is closed. For a narrow band — obesity medicine inside a physician's office, or a practice already licensed by the state in another capacity — the answer is genuinely unsettled, has not been tested by the Medical Licensing Board of Indiana, and will not be settled by anything you read on the internet. Indiana has not issued interpretive guidance, and the rulemaking that would supply it has not been published.

The practical move for a borderline practice is not to pick the answer you prefer. It is to notice that the test turns partly on your own marketing, which is the one input you control. If you want to argue you are outside the chapter, your website has to support the argument before the board asks. If you cannot say that with a straight face, you are inside, and the rest of this guide is your compliance list. Either way, get an Indiana health care lawyer to read the marketing alongside the statute — that is a two-hour engagement, and it is cheaper than the alternative.

The Dates That Are Already Running

Two dates, and Indiana practices conflate them constantly. Getting them straight is the cheapest compliance work available.

July 1, 2026 — the conduct rules

Most of SB 282's substantive obligations took effect on July 1, 2026. That includes the good faith examination requirement, the responsible practitioner duties, adverse event reporting, the location restriction, and the advertising provisions. If your programme has not changed since June, it has been out of step for two months.

January 1, 2027 — registration

Registration with the Medical Licensing Board of Indiana begins January 1, 2027, and the board must maintain a publicly accessible database of registered medical spas. The registration application is reported to require the practice to identify the prescription drugs it uses — including compounded drugs — and to designate a responsible practitioner. Counsel writing on the enrolled act reports that the board's process must be established by October 1, 2026; that is a secondary reading rather than something we have confirmed from the board, so watch the board's own notices before you build a calendar on it.

Why the order is backwards from how owners think about it

The instinct is to treat January as the deadline and July as a warm-up. It is the reverse. Registration is a form; restructuring who examines your weight-loss patients and documenting a responsible practitioner's actual involvement takes a quarter, and that obligation started two months ago. The form is also where the two halves of SB 282 meet: naming your compounded drugs on a state application, in a year when the federal position on compounded GLP-1s has hardened, is a disclosure with consequences.

Who May Prescribe a GLP-1 in Indiana

Verdicts first. Semaglutide and tirzepatide are prescription drugs, so the decision to start a patient on one is prescribing, full stop, regardless of what a programme calls the visit.

Physicians and osteopathic physicians

Verdict: yes, independently. A physician licensed under IC 25-22.5 may evaluate, prescribe, administer, and delegate administration. Under IC 25-22.5-1-1.1 the practice of medicine expressly reaches prescribing and administering drugs, which is the provision that makes every other row on this list a delegation question rather than a scope question.

Nurse practitioners — and the condition Indiana practices get wrong

Verdict: yes, if prescriptive authority is current and the collaboration relationship is intact. An advanced practice registered nurse in Indiana does not hold prescribing power by virtue of the APRN credential. Prescriptive authority comes from a separate board programme at IC 25-23-1-19.5, under which the Indiana State Board of Nursing authorises qualifying APRNs to prescribe, with the authority expiring on October 31 of the odd-numbered year following the year it was granted or renewed. The detailed requirements sit in the board's rules at 848 IAC 5.

That authority is layered on top of the collaboration requirement at IC 25-23-1-19.4, which addresses an advanced practice nurse's collaboration with a licensed practitioner. Indiana remained a restricted practice state through the 2026 session. HB 1116 in 2025 would have removed the practice agreement requirement and did not become law; SB 60 and HB 1129 were filed in the 2026 session to do the same thing. We are not going to tell you how those ended — verify the current status with the Indiana Professional Licensing Agency before you rely on either answer, because this is exactly the kind of fact that goes stale between when a guide is written and when it is read.

What this means operationally is unglamorous and load-bearing: a lapsed collaborative agreement does not merely create a paperwork gap. It removes the footing under every prescription the NP wrote after the lapse, which means every injection those prescriptions authorised, which means every chart in the drawer.

Physician assistants

Verdict: yes, within the four corners of the agreement. Indiana PAs are licensed under IC 25-27.5, and Indiana's PA framework is unusually document-forward. Under IC 25-27.5-5-2 the collaborative agreement must set out the terms of collaboration, and for prescribing it must identify the drug or drug classification being delegated and the protocol the PA will follow. The agreement goes to the board, and amendments must be resubmitted.

For a weight-loss programme that is a gift, because it tells you exactly what good looks like. GLP-1 receptor agonists should be named or clearly classified in the agreement with the titration protocol attached — not inferred from a general grant of authority written when the practice only did filler. If your PA's agreement predates your weight-loss line, it almost certainly does not cover it.

What no one may do

There is no Indiana pathway by which a prescriber's name on a standing protocol substitutes for a prescriber's decision about a patient. A protocol signed in January does not prescribe for a patient who walks in in September. This is the single most common structural defect in weight-loss programmes nationally, and Indiana has now made it visible by putting a named responsible practitioner in a public database.

The Good Faith Examination — Prescribers Only

Most states make you assemble the good faith exam obligation out of a prescribing statute, a nursing position statement, and a board policy that mentions it in passing. Indiana used to be one of them. SB 282 wrote it down, and for weight-loss programmes it is the provision with the most immediate bite.

Who may perform it

A prescriber: a physician, a nurse practitioner, or a physician assistant. A registered nurse may not. That single sentence invalidates the staffing model that dominates weight-loss aesthetics in states without one — an RN who takes the history, weighs the patient, decides they are a candidate, picks the starting dose, injects, and files the chart under a protocol a physician signed months earlier. In Indiana that is no longer a documentation weakness. It means the injection had no lawful order behind it.

What a GLP-1 exam has to reach

Indiana has not published a GLP-1-specific examination checklist, and we are not going to invent one. What we can say is what the standard of care for these agents requires a prescriber to have actually considered, because that is the yardstick a board complaint will be measured against: a height and weight the practice recorded rather than accepted over the phone, a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, pancreatitis history, gallbladder disease, diabetic retinopathy in a diabetic patient, pregnancy status and contraception plans, current medications including insulin and sulfonylureas, and any history of an eating disorder. An exam that does not reach those is unlikely to satisfy the standard of care whether it happened in a room or on a screen.

Does telehealth satisfy it?

Verdict: yes, the medium is not the obstacle. Indiana's telehealth chapter at IC 25-1-9.5 requires a prescriber to establish a provider-patient relationship before prescribing, but it is explicit that establishing that relationship does not require an in-person visit, and it permits a prescription for a patient never previously examined in person provided the prescriber satisfies the applicable standard of care and stays within their scope of practice and certification. The statute also sets minimum relationship steps, including obtaining the patient's name, contact information, and location, and disclosing the prescriber's own name and credential type.

The trap is not the video. It is that SB 282's prescriber-only rule follows the patient onto the screen. A remote encounter conducted by a registered nurse is not a good faith examination in Indiana, and calling it a telehealth visit does not upgrade it. Nor does a questionnaire the patient fills in before a prescriber briefly appears. If your Indiana telehealth flow was designed around throughput, the SB 282 question to ask is simple: which licensed prescriber saw this specific patient, and what does the record show they did?

What a Registered Nurse May and May Not Do

This is where Indiana weight-loss staffing is most concentrated, and where the state's own authority is thinnest — so it deserves an honest treatment rather than a confident one.

Yes: administer on a valid, patient-specific order

Registered nursing under IC 25-23-1-1.1 includes executing a regimen delegated by a physician holding an unlimited licence to practise medicine or osteopathic medicine, alongside executing a nursing regimen and delegating and evaluating nursing practice. Administering a subcutaneous injection a prescriber has ordered for a named patient sits comfortably inside that. Nothing in SB 282 removed it.

No: assess, prescribe, or adjust the dose

Everything upstream of administration belongs to a prescriber. The RN may not perform the good faith examination, may not decide the patient is a candidate, may not select the starting dose, and — the one Indiana programmes rationalise hardest — may not raise, hold, or lower a dose based on how the patient is tolerating it. A titration decision is a prescribing decision in operational clothing. If your protocol says increase at four weeks unless the patient reports nausea and the nurse decides whether the nausea counts, a prescriber is not making the call.

The commentary split, stated plainly

Since SB 282 passed, some Indiana commentary has taken a stricter line, reading the state as keeping medical aesthetic procedures — injectables included — away from registered nurses entirely. We do not think the statute says that: SB 282 regulates the facility, the responsible practitioner, the examination, and the reporting duty, and it does not enumerate who may perform each procedure. But Indiana has no board rule and no published State Board of Nursing position statement squarely resolving cosmetic or weight-loss injection by an RN, which is precisely why reasonable readers are landing in different places.

Where a state is silent and its commentators disagree, the defensible structure is the conservative one: a patient-specific prescriber order rather than a standing protocol, written administration procedures, documented competency for each nurse before they inject, and a prescriber genuinely reachable when something goes wrong. Our GLP-1 injection protocol guide covers what that documentation looks like in practice, and the same discipline applies whichever way Indiana eventually lands.

What the Responsible Practitioner Owes

SB 282's most structurally significant move is not registration. It is that Indiana now requires a named human being to be accountable for a medical spa's clinical care, and puts that name where the public can find it.

The role the statute created

Every registered medical spa must designate a responsible practitioner, and the role must be held by a licensed practitioner with prescriptive authority in Indiana — in practice a physician, nurse practitioner, or physician assistant. The statute assigns duties rather than a title, and requires the person to spend a sufficient amount of time on site. That last phrase is aimed squarely at the absentee medical director arrangement, in which a physician's name and licence number appear on a protocol binder they have never opened.

What is still undefined

Indiana has not said what sufficient means in hours, and the Medical Licensing Board's rulemaking is where that will be settled. Anyone quoting you a specific weekly on-site requirement today is quoting an assumption. What we would not do is treat the absence of a number as permission to keep the old arrangement: the duty is live as of July 1, 2026 even though its measurement is not, and a board assessing whether oversight was sufficient after an adverse event will not be constrained by the fact that it never published a threshold.

What a weight-loss programme should give the role

For a GLP-1 programme specifically, the responsible practitioner's involvement should be visible in the file rather than asserted in a contract: who approved the titration protocol and when it was last reviewed, who signs off on patients outside the standard candidacy criteria, who is reachable during treatment hours, and how adverse events reach them. Our Indiana med spa regulations profile tracks the state-level detail as the board's rules develop, with primary sources cited.

Indiana's Weight-Loss Prescribing Rules That Predate SB 282

Here is the part almost no GLP-1 guide covers, because it is Indiana-specific and older than the current wave. Indiana has had targeted rules about prescribing for weight reduction on the books for years, and a med spa that offers GLP-1s alongside anything else needs to know where they bite.

Schedule II is off the table for weight reduction

Under 844 IAC 5-2-20, a physician may not utilise, prescribe, order, dispense, administer, supply, sell, or give any amphetamine or sympathomimetic amine drug or compound designated as a Schedule II controlled substance to any person for purposes of weight reduction or control in the treatment of obesity. That is a flat prohibition, not a conditional one, and it is a Medical Licensing Board rule rather than a guideline.

Schedule III and IV: prescriber-only, with conditions attached

Indiana also addresses the next tier by statute. Under IC 35-48-3-11, only a physician licensed under IC 25-22.5, a physician assistant licensed under IC 25-27.5, or an advanced practice registered nurse licensed under IC 25-23 with prescriptive authority may treat a patient with a Schedule III or Schedule IV controlled substance for the purpose of weight reduction or to control obesity — and even then only on conditions the section sets out, including a duty to discontinue the drug once it is determined the patient has failed to lose weight on the treatment plan.

Why this matters to a GLP-1 clinic

Semaglutide and tirzepatide are not controlled substances, so neither provision governs a GLP-1 prescription directly, and we want to be exact about that rather than let a scary-sounding citation do work it cannot do. The relevance is threefold. First, most Indiana weight-loss practices do not sell only GLP-1s — phentermine sits on the same menu, and phentermine is Schedule IV. Second, the roster in IC 35-48-3-11 tells you how Indiana thinks about weight-loss pharmacotherapy generally: it is prescriber work, and the state has been willing to say so by name. Third, the discontinuation duty in that section is the closest thing Indiana has to an explicit statement that a weight-loss drug programme is supposed to be reassessed rather than renewed indefinitely — an expectation that will read across to GLP-1 monitoring even though the section does not reach the drug.

If you are building the programme rather than auditing one, the practical starting point is a written schedule of what gets measured and when. Our GLP-1 monitoring schedule template lays out the visit cadence, and the tirzepatide protocol guide handles the second molecule, which most programmes bolt on without rewriting anything.

Charting and Monitoring an Indiana GLP-1 Programme

Indiana has not published a GLP-1 charting rule, and we will not manufacture one. What Indiana has done is change who reads the file, and that is a more useful thing to design around.

Three readers, one record

Before SB 282, an Indiana weight-loss chart had a realistic audience of one: a plaintiff's lawyer, eventually. Now there are three plausible readers with authority. The Medical Licensing Board of Indiana registers the facility, holds the responsible practitioner accountable, and receives adverse event reports. The Indiana State Board of Nursing arrives if a nurse's participation is questioned. The Indiana Board of Pharmacy arrives if the drug's origin is questioned, which is a new exposure created by the compounding half of the same act. A chart built to satisfy only the first of those is now incomplete.

What the record has to show

Taking the three readers together, an Indiana GLP-1 file should make each of these findable without reconstruction: who performed the good faith examination and their prescriber credential; the screening that supported candidacy, including the contraindication history above; the order authorising each injection, tied to the patient rather than a protocol; the product's identity and source, including lot number and whether it was compounded; the dose and date of every administration and who administered it; the titration decision, the prescriber who made it, and what it was based on; weight, tolerance, and adverse effects at each visit; and what was disclosed at consent — compounded status included, if applicable. Our med spa consent forms guide covers the disclosure side, which is the element weight-loss programmes most often carry over unmodified from an injectables consent that never contemplated a compounded drug.

The 15-day adverse event report

SB 282 requires a serious adverse event — reported as a death, a life-threatening medical event, or a hospitalisation — to be reported to the board within 15 days. For a GLP-1 programme the realistic triggers are pancreatitis, severe dehydration from protracted vomiting, gallbladder events, and hypoglycaemia in a patient also taking insulin or a sulfonylurea. Fifteen days sounds generous until you notice that the clock starts before anyone in the practice has decided whether the event was your fault. Build the reporting decision into your adverse-event procedure now, with a named person who owns it, rather than discovering the obligation while a patient is still admitted.

Compounded Semaglutide and Tirzepatide: Where the Federal Position Actually Stands

This has moved more than once, and repeating a 2024 answer in 2026 is how practices end up on the wrong side of an enforcement letter. Here is the current position, with the dates.

The shortage ended, and the justification went with it

The FDA declared the tirzepatide shortage resolved in December 2024 and the injectable semaglutide shortage resolved on February 21, 2025, then set phased wind-down dates: 503A compounding pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025. Those dates matter because the shortage listing was the legal hook. Neither a 503A pharmacy nor a 503B facility may compound a drug that is essentially a copy of a commercially available approved product, and the shortage exemption was what had made mass-market compounded semaglutide possible in the first place. Litigation by the Outsourcing Facilities Association failed to secure preliminary injunctions against that position.

503A versus 503B in 2026

The distinction still matters, and it is the thing most Indiana buyers get wrong on a sales call. A 503A pharmacy compounds against an individual patient-specific prescription under state board of pharmacy oversight. A 503B outsourcing facility registers with the FDA and may produce without patient-specific prescriptions, which is what makes office stock possible — and it is the model that has been squeezed hardest. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it had not identified sufficient clinical need for outsourcing facilities to compound them from bulk substances, and took comments through June 29, 2026. As of this writing that proposal is pending rather than final — we have not been able to confirm a final determination, so treat any claim that the door is definitively shut, or definitively open, as ahead of the record.

What remains is narrow and patient-specific: a documented clinical need that the approved product cannot meet — a genuine allergy to an inactive ingredient, or a dose the commercial presentations cannot deliver — supported in the chart before the order is placed rather than reverse-engineered after. Our 503A versus 503B sourcing guide works through how to evaluate a supplier and what to ask for in writing.

Indiana's own compounding chapter

This is where SB 282's other half lands on your programme. The act applies to compounding concerning a glucagon-like peptide-1 substance used for weight management, requires compounders to comply with provisions of the federal Food, Drug, and Cosmetic Act, and puts the Indiana Board of Pharmacy in the position of investigating and enforcing compliance by compounding pharmacies. The chapter defines bulk drug substance by reference to 21 CFR 207.3, requires that a bulk drug substance be manufactured by an establishment registered under 21 U.S.C. 360, and requires persons selling, transferring, or distributing the compounded drug to maintain specified records.

Read that last clause as a med spa owner rather than a pharmacist. A practice that administers or dispenses a compounded GLP-1 is in the distribution chain the chapter cares about, and it will be naming those compounded drugs on a registration application from January 2027. Indiana has, quietly, given itself a way to compare what you told the Medical Licensing Board you use against what the Board of Pharmacy can see about where it came from.

The personal-use and research-use-only traps

Two shortcuts are circulating in Indiana and both are worse than they look. The first is personal importation or a physician ordering API for the practice to reconstitute in-house: compounding by the practice is compounding, it sits under state pharmacy law, and doing it without the appropriate licensure is not cured by the fact that a physician did it. The second is the peptide vial sold with research use only and not for human consumption on the label. The FDA has rejected that framing directly — on April 7, 2026 it published seven warning letters against online peptide sellers marketing GLP-1 copycats as research use only, on the basis that the disclaimers did not matter when the product pages themselves described appetite suppression, weight loss, and glucose regulation. Independent testing of gray-market peptides has repeatedly found contamination, incorrect sequences, and substandard purity. There is no version of this that survives a board complaint, and a practice that wants a defensible programme should be shopping for med spa compliance SOPs and a licensed supplier rather than for a cheaper vial.

Advertising a GLP-1 Programme in Indiana

SB 282 did something here that is easy to skim past and specifically dangerous for weight-loss marketing.

The new deceptive trade practice

Under the act, a medical spa engages in a deceptive trade practice if it misrepresents that a prescription medication has FDA approval, or that it functions similarly to another drug approved by the FDA. Sit with that second clause. The entire retail vocabulary of compounded GLP-1 marketing — the same active ingredient as Wegovy, works just like Ozempic, generic semaglutide — is a claim that a compounded product functions similarly to an approved drug. Indiana has now named that as a deceptive practice by statute rather than leaving it to a general consumer protection theory.

What the board can do about it

The Medical Licensing Board may investigate, may suspend a registration for deceptive or misleading advertising, and may refer licensed practitioners to their own governing boards. That is a meaningfully different enforcement posture from a consumer complaint: the facility's ability to operate and the individual clinician's licence are both in play, from the same file, and the registration status is public. None of this displaces the FTC's substantiation requirements or Indiana's general consumer protection law — it stacks on top of them.

The practical audit

Read your own funnel the way a board would, in this order: the ad, the landing page, the booking flow, the intake form, and the text messages your staff send. Remove brand-comparison language for compounded products, average-loss numbers you cannot substantiate from your own records, and before-and-after images without disclosure of what else the patient was doing. Then check who is speaking in the copy — a page your responsible practitioner has never reviewed is a problem waiting for a screenshot. If you also inject, our guide to who can inject Botox in Indiana covers the same statute from the injectables side, and the rest of the cluster lives on the Indiana med spa compliance hub.

Where Indiana Is Silent, and What to Do About It

A guide that pretends to certainty it does not have is worse than useless in a state mid-rulemaking, so here is the honest inventory of what Indiana has not yet answered.

The open items

The board has not defined what a sufficient amount of on-site time means for a responsible practitioner. It has not published registration fees, forms, or renewal mechanics. It has not issued interpretive guidance on the boundary of the medical spa definition, including the physician-office question this guide opened with. The State Board of Nursing has not resolved cosmetic or weight-loss injection by an RN. And the federal 503B bulks list determination is pending. Each of those is a live variable, not a settled rule, and any consultant who quotes you a number for one of them is quoting themselves.

How to build against uncertainty

The answer is not to wait. Every open item above concerns a threshold, not a direction — nobody expects the board to decide that less oversight is acceptable, or that RNs may examine patients after all. So build to the stricter reading of each: a prescriber performs every examination, every injection has a patient-specific order behind it, the responsible practitioner's involvement is documented rather than contractual, compounded product is patient-specific and justified in the chart, and the marketing makes no comparison claims. A practice built that way is compliant under every plausible version of the rules that follow, and it is the same practice you would want to own if none of this had passed.

Frequently Asked Questions